Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses

Core Insights - The CENTERSTONE study demonstrates that a single-dose of Xofluza significantly reduces the transmission of influenza from infected individuals to household members, marking a first in antiviral treatment for respiratory viral illnesses [1][2][3] - The study's results indicate that reducing household transmission could alleviate the overall burden of seasonal and pandemic influenza on healthcare systems [1][3] Company Overview - Roche announced positive topline results from the phase III CENTERSTONE study, which involved over 4,000 participants across 272 global sites [4] - Xofluza is a first-in-class antiviral approved in over 80 countries for treating uncomplicated influenza types A and B, representing a significant innovation in influenza treatment [5][6] Study Details - The CENTERSTONE study was a randomized, placebo-controlled trial that assessed the efficacy of Xofluza taken within 48 hours of symptom onset to reduce onward transmission of influenza [4] - The primary endpoint was the proportion of household contacts who tested positive for influenza within five days after treatment, with secondary endpoints focusing on symptom development [4] Public Health Impact - Seasonal influenza affects approximately one billion people annually, leading to millions of hospitalizations and up to 650,000 deaths worldwide [3][7] - The new evidence from the CENTERSTONE study could enhance public health strategies for influenza pandemic preparedness [3][2]